Reporting of transactions in Orphazyme’s shares made by persons discharging managerial responsibilities - Seite 3
Orphazyme A/S
b) LEI code
54930025OZD2GGSQ7L42
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a) Description of the financial instrument, type of instrument and identification code
Shares
ISIN DK0060910917
b) Nature of the transaction
Purchase of shares from Martijn Kleijwegt
c) Price(s) and volume(s)
Price(s) | Volume(s) | |
EUR | - | 1,927 |
d) Aggregated information
Aggregated volume: 1,927 shares
Aggregated price: EUR 1
Price per share (volume weighted average): EUR -
e) Date of the transaction
March 24, 2021
f) Place of the transaction
Outside a trading venue
For additional information, please contact
Orphazyme A/S
Anders Vadsholt, Interim CEO & CFO +45 28 98 90 55
About Orphazyme A/S
Orphazyme is a late-stage biopharmaceutical company pioneering the Heat Shock Protein response for the treatment of neurodegenerative orphan diseases. The company is harnessing amplification of
Heat Shock Proteins (or HSPs) in order to develop and commercialize novel therapeutics for diseases caused by protein misfolding, protein aggregation, and lysosomal dysfunction, including
lysosomal storage diseases and neuromuscular degenerative diseases. Arimoclomol, the company’s lead candidate, is in clinical development for four orphan diseases: Niemann-Pick disease type C
(NPC), Amyotrophic Lateral Sclerosis (ALS), Inclusion Body Myositis (IBM) and Gaucher disease. Orphazyme is headquartered in Denmark and has operations in the U.S. and Switzerland. Orphazyme’s
shares are listed on Nasdaq U.S. (ORPH) and Nasdaq Copenhagen (ORPHA).
Lesen Sie auch
About arimoclomol
Arimoclomol is an investigational drug candidate that amplifies the production of Heat Shock Proteins (HSPs). HSPs can rescue defective
misfolded proteins, clear protein aggregates, and improve the function of lysosomes. Arimoclomol is administered orally and has now been studied in seven phase 1, four phase 2 and one pivotal phase
2/3 trial. Arimoclomol is in clinical development for NPC, Gaucher Disease, IBM, and ALS. Arimoclomol has received orphan drug designation (ODD) for NPC, IBM, and ALS in the US and EU. Arimoclomol
has received fast-track designation (FTD) from the U.S. Food and Drug Administration (FDA) for NPC, IBM and ALS. In addition, arimoclomol has received breakthrough therapy designation (BTD) and
rare-pediatric disease designation (RPDD) from the FDA for NPC.